Search Results for: L’alcool danneggia il DNA e aumenta il rischio di cancro.

Vendute al supermercato, marche diverse ma stesso stabilimento

Ascierto, ‘7 insospettabili errori da non fare mai in estate’

Nei neonati riduce il rischio di ricovero e terapia intensiva

This past year, 2024, brought many exciting practice-changing publications to JAMA Oncology across a wide variety of topics. Throughout the year, we published several randomized clinical trials that changed the course of clinical care and a substantial number of studies on cancer survivorship. These articles addressed how to ameliorate the long-term adverse effects of treatment and also how to identify long-term health risks. We continued to receive works defining the persistent impacts of COVID-19 infections and mandates on oncology patients. The science of oncology also filled our journal with topics ranging from unraveling the microbiome and how its composition affects oncologic outcomes, defining new biomarkers to better predict responses to immunotherapy, and advances in circulating or cell-free DNA analysis as prognostic or predictive tools. We have also seen machine learning and artificial intelligence address important clinical questions that will add precision to everyday practice, and we look forward to informatics as a growing sector of the journal.

Prima e dopo la chirurgia. Primo studio positivo in oltre vent’anni

The AHA has revisited its recommendations for managing blood culture–negative endocarditis in light of new diagnostic approaches such as sequencing of microbial DNA in plasma.

Introduction
Halitosis is a term that defines any unpleasant odour smell originating from the oral cavity and may have a local or systemic origin. This project aims to determine the effectiveness of treatment involving antimicrobial photodynamic therapy (aPDT) combined with treatment using probiotics at reducing halitosis.

Methods and analysis
92 individuals from 18 to 60 years of age with a diagnosis of halitosis (sulfide≥112 ppb, gas chromatography) will be selected. The participants will be randomly allocated to four groups (n=23). Group 1 (control): brushing, dental floss and tongue scraper; group 2: brushing, dental floss, tongue scraper and aPDT with blue Light Emitting Diode (LED) +annatto; group 3: brushing, dental floss, tongue scraper and aPDT with blue Light Emitting Diode (LED) +annatto and probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12); and group 4: brushing, dental floss, tongue scraper and probiotic lozenges containing S. salivarius K12 (BLIS K12). Comparisons will be made of the respiratory analysis results before and immediately after the first treatment session, at the end of the 30-day treatment period and again 60 days after the treatment initiation. Microbiological analysis (counts of colony-forming units of viable bacteria from coated tongue) will be performed at the same time. The microbiome analysis will be conducted before treatment, 30 days after treatment completion and 60 days after treatment initiation, following DNA extraction. All groups will receive oral hygiene instructions as well as brushes, toothpaste and dental floss. Data normality will be checked using Shapiro-Wilk test. In the case of normality, analysis of variance is used for the comparisons. In the case of non-parametric data, Kruskal-Wallis test will be used. Wilcoxon test will be used to analyse the results of each treatment between two assessment times.

Ethics and dissemination
This protocol has been approved by the Human Research Ethics Committee of Nove de Julho University (certificate number: 82830524.6.0000.5511; approval date: 2 October 2024). Participants will agree to take part in the study by signing an informed consent form. The findings will be published in a peer-reviewed journal. The collected data will be available in the OSF data repository.

Trial registration number
NCT06583720.

L’esperta: resta un test fondamentale ma l’abuso è causa del 5% dei casi